Pipeline

Through joint collaborations with top pharmaceutical companies and research institutions, KREX has been used to identify autoantibody biomarkers for commercial diagnostics and screening applications. In addition, KREX has also been used to identify biologics with therapeutics potential.

Stage

Project

Pilot

Candidate id

Validation

Clinical Trial

Commercialisation

Companion Diagnostics

Cancer Immunotherapy PD1 inhibitor

Autoimmune Disease Drug 1

Autoimmune Disease Drug 2

Disease Diagnostics

Melanoma

NSCLC

Gastric Cancer

Breast Cancer

Therapeutic Autoantibodies

Rheumatoid Arthritis – A

Autism

Lupus

Parkinson’s

Aging

Rheumatoid Arthritis – B

Featured Products

IMMUNOME™

High-throughput platform of 1600+ immunomodulatory proteins

CTA array

High-throughput protein array of
200+ cancer-testis antigens

Custom array

Flexible miniaturised format for
high-throughput screening

1996 – 2018 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X